RxDoctor Payments Data

Mumtaz Husain, MD

Internal Medicine · East Liverpool, OHNPI 1295751113

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 206 payments — averaging $17.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$524
  • Lilly USA, LLC$515
  • Novo Nordisk$209
  • Amgen$186
  • Abbott$180
  • Pfizer$179
  • plus $2K from 33 others

What the payments were for

  • Food & beverage$3,532100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$102,704
Medicare patients
152
Services billed
1,539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide154$184,553
EliquisApixaban263$123,654
NuplazidPimavanserin Tartrate24$57,804
JardianceEmpagliflozin80$56,860
XareltoRivaroxaban75$46,644
RexultiBrexpiprazole24$31,054
NuedextaDextromethorphan Hbr/Quinidine13$23,329
Breo ElliptaFluticasone/Vilanterol37$18,586
OzempicSemaglutide16$15,359
TrulicityDulaglutide11$11,019
Fluticasone-SalmeterolFluticasone Propion/Salmeterol63$9,952
RivastigmineRivastigmine Tartrate119$8,747
Lurasidone Hcl20$8,387
Gabapentin461$8,157
Paliperidone ErPaliperidone13$8,094

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$515$195,572165 claims
PfizerEliquis$179$123,654263 claims
Boehringer IngelheimJardiance, Tradjenta$29$63,20292 claims
Johnson & JohnsonXarelto$130$46,64475 claims
Avanir Pharmaceuticals, Inc.Nuedexta$12$23,32913 claims
GSKBreo Ellipta$81$18,58637 claims
Novo NordiskOzempic$209$15,35916 claims
NovartisEntresto$17$6,51216 claims
AstraZenecaSymbicort$524$3,05015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in East Liverpool

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →